Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Randomized, Single Dose, Cross Over Study to Estimate the Relative Bioavailability of a Varenicline (CP-526,555) Transdermal Delivery System to the Chantix Immediate Release Tablet Formulation in Adult Smokers

NCT00661765 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00661765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00661765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Randomized, Single Dose, Cross Over Study to Estimate the Relative Bioavailability of a Varenicline (CP-526,555) Transdermal Delivery System to the Chantix Immediate Release Tablet Formulation in Adult Smokers
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2008
Completion date
June 30, 2008
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

smoking cessation